Surrogate outcomes: experiences at the Common Drug Review
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 11 (1) , 31
Abstract
Surrogate outcomes are a significant challenge in drug evaluation for health technology assessment (HTA) agencies. The research objectives were to: identify factors associated with surrogate use and acceptability in Canada’s Common Drug Review (CDR) recommendations, and compare the CDR with other HTA or regulatory agencies regarding surrogate concerns.Keywords
This publication has 25 references indexed in Scilit:
- Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictionsClinicoEconomics and Outcomes Research, 2013
- Common Drug Review RecommendationsPharmacoEconomics, 2012
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Surrogate outcomes in health technology assessment: An international comparisonInternational Journal of Technology Assessment in Health Care, 2009
- Use of surrogate outcomes in cost-effectiveness models: A review of United Kingdom health technology assessment reportsInternational Journal of Technology Assessment in Health Care, 2009
- Optimizing the use of prescription drugs in Canada through the Common Drug ReviewCanadian Medical Association Journal, 2008
- Tips for Teachers of Evidence-Based Medicine: Understanding Odds Ratios and Their Relationship to Risk RatiosJournal of General Internal Medicine, 2008
- The Role of Surrogate Endpoints in the Evaluation of Efficacy and Safety of Therapeutic Interventions in Diabetes MellitusThe Review of Diabetic Studies, 2008
- Methodological issues in the economic analysis of cancer treatmentsEuropean Journal of Cancer, 2006
- Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, StrategiesAnnual Review of Pharmacology and Toxicology, 2001